<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:06:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10008324" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10008324</identifier>
        <datestamp>2023-03-13</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10008324</article-id>
              <article-id pub-id-type="pmcid">PMC10008324</article-id>
              <article-id pub-id-type="pmc-uid">10008324</article-id>
              <article-id pub-id-type="pmid">36898748</article-id>
              <article-id pub-id-type="pmid">36898748</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2022-066995</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2022-066995</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Intensive Care</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1707</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-100256924" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1092-3533</contrib-id>
                  <name>
                    <surname>Qian</surname>
                    <given-names>Edward Tang</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-75046436" contrib-type="author">
                  <name>
                    <surname>Casey</surname>
                    <given-names>Jonathan D</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-88117712" contrib-type="author">
                  <name>
                    <surname>Wright</surname>
                    <given-names>Adam</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-75103489" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Li</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-100257287" contrib-type="author">
                  <name>
                    <surname>Siemann</surname>
                    <given-names>Justin</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-100257333" contrib-type="author">
                  <name>
                    <surname>Dear</surname>
                    <given-names>Mary Lynn</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-87642817" contrib-type="author">
                  <name>
                    <surname>Stollings</surname>
                    <given-names>Joanna</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-68815981" contrib-type="author">
                  <name>
                    <surname>Lloyd</surname>
                    <given-names>Bradley Daniel</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-100257384" contrib-type="author">
                  <name>
                    <surname>Seitz</surname>
                    <given-names>Kevin</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-100257394" contrib-type="author">
                  <name>
                    <surname>Nelson</surname>
                    <given-names>George</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-100257412" contrib-type="author">
                  <name>
                    <surname>Wright</surname>
                    <given-names>Patty</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-64835945" contrib-type="author">
                  <name>
                    <surname>Siew</surname>
                    <given-names>Edward D</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-100257429" contrib-type="author">
                  <name>
                    <surname>Dennis</surname>
                    <given-names>Bradley</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib id="author-100257437" contrib-type="author">
                  <name>
                    <surname>Wrenn</surname>
                    <given-names>Jesse</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-100257456" contrib-type="author">
                  <name>
                    <surname>Andereck</surname>
                    <given-names>Jonathan</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-68816206" contrib-type="author">
                  <name>
                    <surname>Self</surname>
                    <given-names>Wesley H</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-75103546" contrib-type="author" equal-contrib="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7664-8263</contrib-id>
                  <name>
                    <surname>Semler</surname>
                    <given-names>Matthew W</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-75103538" contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Rice</surname>
                    <given-names>Todd W</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>Vanderbilt Learning Healthcare System Platform Investigators
<contrib-group content-type="collaborators"><contrib contrib-type="collab"><name><surname>Bernard</surname><given-names>Gordon</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Dittus</surname><given-names>Bob</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Dwyer</surname><given-names>Shon</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Freundlich</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Gatto</surname><given-names>Cheryl</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Harrell</surname><given-names>Frank</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Harris</surname><given-names>Paul</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Hartert</surname><given-names>Tina</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Hayman</surname><given-names>Jim</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Ivory</surname><given-names>Catherine</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Kleinpell</surname><given-names>Ruth</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Kripalani</surname><given-names>Sunil</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Lindsell</surname><given-names>Christopher</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Liska</surname><given-names>Lee Ann</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Luther</surname><given-names>Patrick</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Morrison</surname><given-names>Jay</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Nantais</surname><given-names>Thomas</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Pulley</surname><given-names>Jill</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Rehm</surname><given-names>Kris</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Rice</surname><given-names>Todd</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Rothman</surname><given-names>Russell</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Semler</surname><given-names>Matt</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Steaban</surname><given-names>Robin</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Walker</surname><given-names>Philip</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Wilkins</surname><given-names>Consuelo</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Wright</surname><given-names>Adam</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Zuckerman</surname><given-names>Autumn</given-names></name></contrib></contrib-group>
</collab>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Division of Allergy, Pulmonary, and Critical Care Medicine</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Biomedical Informatics</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Biostatistics</institution>, <institution>Vanderbilt University School of Medicine</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Vanderbilt Institute for Clinical and Translational Research</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Department of Pharmaceutical Services</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Department of Emergency Medicine</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Division of Infectious Disease</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Division of Nephrology and Hypertension</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">Department of Surgery</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Edward Tang Qian; <email>edward.t.qian@vumc.org</email>
</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>10</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>3</issue>
              <elocation-id>e066995</elocation-id>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>02</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-03-10">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2022-066995.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2022-066995.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2022-066995.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Antibiotics are time-critical in the management of sepsis. When infectious organisms are unknown, patients are treated with empiric antibiotics to include coverage for gram-negative organisms, such as antipseudomonal cephalosporins and penicillins. However, in observational studies, some antipseudomonal cephalosporins (eg, cefepime) are associated with neurologic dysfunction while the most common antipseudomonal penicillin (piperacillin–tazobactam) is associated with acute kidney injury (AKI). No randomised control trials have compared these regimens. This manuscript describes the protocol and analysis plan for a trial designed to compare the effects of antipseudomonal cephalosporins and antipseudomonal penicillins among acutely ill patients receiving empiric antibiotics.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>The Antibiotic Choice On ReNal outcomes trial is a prospective, single-centre, non-blinded randomised trial being conducted at Vanderbilt University Medical Center. The trial will enrol 2500 acutely ill adults receiving gram-negative coverage for treatment of infection. Eligible patients are randomised 1:1 to receive cefepime or piperacillin–tazobactam on first order entry of a broad-spectrum antibiotic covering gram-negative organisms. The primary outcome is the highest stage of AKI and death occurring between enrolment and 14 days after enrolment. This will be compared between patients randomised to cefepime and randomised to piperacillin–tazobactam using an unadjusted proportional odds regression model. The secondary outcomes are major adverse kidney events through day 14 and number of days alive and free of delirium and coma in 14 days after enrolment. Enrolment began on 10 November 2021 and is expected to be completed in December 2022.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The trial was approved by the Vanderbilt University Medical Center institutional review board (IRB#210591) with a waiver of informed consent. Results will be submitted to a peer-reviewed journal and presented at scientific conferences.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT05094154" ext-link-type="ClinicalTrials.gov">NCT05094154</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Adult intensive &amp; critical care</kwd>
                <kwd>Nephrology</kwd>
                <kwd>INFECTIOUS DISEASES</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id>
                      <institution>National Center for Advancing Translational Sciences</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UL1 TR002243</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>Strengths and limitations of this study</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>This ongoing pragmatic trial will compare the effects of cefepime versus piperacillin–tazobactam on acute kidney injury (AKI) and death among acutely ill adults receiving gram-negative antibiotic therapy in the emergency department or intensive care unit.</p>
                </list-item>
                <list-item>
                  <p>Strengths: Broad eligibility criteria, inclusion of a range of indications for antibiotic therapy and use of the electronic health record to screen for eligible patients and facilitate delivery of the assigned intervention will increase the external validity of the findings.</p>
                </list-item>
                <list-item>
                  <p>Limitations: After concealed randomisation, patients, clinicians and investigators are unblinded to study group assignment. Because urine output is not systematically available across all care, the outcome of AKI is based on creatinine measurements.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Antibiotics are necessary for the management of patients with sepsis,<xref rid="R1" ref-type="bibr">1</xref> but can cause unintended adverse effects on organ function.<xref rid="R2" ref-type="bibr">2</xref> Since specific organisms causing infection are often unknown, empiric broad-spectrum antibiotics are commonly prescribed. For patients at risk for resistant organisms, common regimens include gram-positive coverage (ie, vancomycin) and gram-negative coverage with an antipseudomonal cephalosporin or penicillin, predominantly cefepime or piperacillin–tazobactam.<xref rid="R1" ref-type="bibr">1</xref>
</p>
              <p>No prospective randomised trials have compared the efficacy of cefepime versus piperacillin–tazobactam head to head. When administered empirically in clinical practice, both antibiotics are commonly considered to have comparable activity against gram-negative organisms, including <italic toggle="yes">Pseudomonas,</italic> although cefepime does not cover anaerobic organisms and piperacillin–tazobactam does. Whether coverage of anaerobic organisms in acutely ill patients is associated with higher<xref rid="R3" ref-type="bibr">3</xref> mortality, lower<xref rid="R4" ref-type="bibr">4–7</xref> mortality or no difference in mortality is uncertain.</p>
              <p>In the absence of evidence that efficacy differs between cefepime and piperacillin–tazobactam, discussion surrounding the choice between the two has focused on adverse effects. Some observational studies have reported an association between receipt of piperacillin–tazobactam and acute kidney injury (AKI),<xref rid="R8" ref-type="bibr">8 9</xref> particularly among patients receiving vancomycin.<xref rid="R10" ref-type="bibr">10–12</xref> Other studies have shown no relationship between piperacillin–tazobactam and AKI.<xref rid="R13" ref-type="bibr">13 14</xref> Adverse kidney events are common during hospitalisation,<xref rid="R15" ref-type="bibr">15</xref> and there are many potential contributors including isotonic fluids,<xref rid="R16" ref-type="bibr">16 17</xref> medications and acute illnesses such as sepsis.<xref rid="R18" ref-type="bibr">18 19</xref>
</p>
              <p>Similarly, an association between cephalosporins and neurotoxicity manifesting as delirium and coma has been observed.<xref rid="R20" ref-type="bibr">20–22</xref> Delirium, acute brain dysfunction characterised by fluctuations in mental status, inattention, altered consciousness and disorganised thinking,<xref rid="R23" ref-type="bibr">23</xref> is also a common complication of hospitalisation. In intensive care unit (ICU) populations, delirium is predictive of mortality, prolonged length of stay and long-term cognitive impairment.<xref rid="R24" ref-type="bibr">24 25</xref> The incidence of cephalosporin-induced neurotoxicity is unknown but has been reported to increase in-hospital mortality.<xref rid="R26" ref-type="bibr">26</xref>
</p>
              <p>A randomised controlled trial would overcome limitations of observational data, but none is known to exist.<xref rid="R27" ref-type="bibr">27</xref> Rigorous, high-quality evidence assessing the risk of AKI and neurotoxicity after exposure to antipseudomonal antibiotics would have the potential to change care received by thousands of acutely ill adults annually. To address the lack of available evidence, we are conducting a prospective, randomised trial comparing antipseudomonal cephalosporins and antipseudomonal penicillins among acutely ill adults in the emergency department (ED) or ICU.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <p>This manuscript was written in accordance with Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (<xref rid="T1" ref-type="table">table 1</xref>, <xref rid="SP1" ref-type="supplementary-material">online supplemental file 1</xref>).<xref rid="R28" ref-type="bibr">28</xref> The Learning Healthcare System (LHS) Platform at Vanderbilt University Medical Center conducts research studies using a unique model that leverages pragmatic, randomised, controlled clinical trials embedded within usual care.<xref rid="R29" ref-type="bibr">29</xref> The LHS Platform is composed of stakeholders from across the enterprise and supports projects in both the paediatric and adult inpatient and outpatient settings (<xref rid="SP1" ref-type="supplementary-material">online supplemental file 2</xref>). LHS Platform studies focus on comparative effectiveness, implementation science and programmatic evaluation approaches.<xref rid="R30" ref-type="bibr">30 31</xref>
</p>
              <supplementary-material id="SP1" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1136/bmjopen-2022-066995.supp1</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="SS1" xlink:href="bmjopen-2022-066995supp001.pdf" content-type="local-data"/>
                </p>
              </supplementary-material>
              <table-wrap position="float" id="T1">
                <label>Table 1</label>
                <caption>
                  <p>Standard Protocol Items: Recommendations for Interventional Trials checklist</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="2" colspan="1"/>
                      <td align="left" valign="bottom" rowspan="1" colspan="5">Study period</td>
                    </tr>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Eligibility<break/>screen</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Randomisation<break/>and allocation</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="2">Post allocation</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Final outcome<break/>assessment</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>Timepoint</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Order entry for CEF or PTZ</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">EHR enrolment advisor</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7 days after enrolment</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">14 days after enrolment</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Discharge or 28 days after enrolment</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>Enrolment:</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">EHR-based inclusion criteria screening</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Manual screening for exclusion criteria by treating clinicians</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Allocation</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>Interventions:</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="4"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Cefepime</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Piperacillin–tazobactam</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>Assessments:</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="4"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Baseline variables</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Adverse events</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Primary and secondary outcomes</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Exploratory outcomes</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T1_FN1">
                    <p>Enrolment, interventions and assessments.</p>
                  </fn>
                  <fn id="T1_FN2">
                    <p>CEF, cefepime; EHR, electronic health record; PTZ, piperacillin–tazobactam.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="s2-1">
                <title>Study design</title>
                <p>The Antibiotic Choice On ReNal outcomes (ACORN) trial is a pragmatic, single-centre, unblinded, parallel-group, randomised trial comparing antipseudomonal cephalosporins to antipseudomonal penicillins among acutely ill adults receiving gram-negative antibiotics in the ED and ICU. At this centre, the predominant antipseudomonal cephalosporin is cefepime and the predominant antipseudomonal penicillin is piperacillin–tazobactam. The primary outcome is the highest stage of AKI or death in 14 days. The trial protocol was approved by the institutional review board at Vanderbilt University Medical Center and registered prior to initiation of enrolment (NCT05094154). An independent data and safety monitoring board (DSMB) monitors the progress and safety of the trial.</p>
              </sec>
              <sec id="s2-2">
                <title>Patient and public involvement</title>
                <p>Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research. Patient and community representatives participated in the steering committee for the LHS in which the trial was conducted.</p>
              </sec>
              <sec id="s2-3">
                <title>Study population</title>
                <sec id="s2-3-1">
                  <title>Inclusion criteria</title>
                  <list list-type="order">
                    <list-item>
                      <p>Age≥18 years old.</p>
                    </list-item>
                    <list-item>
                      <p>Located in a participating ED or ICU.</p>
                    </list-item>
                    <list-item>
                      <p>Less than 12 hours between presentation to study hospital.</p>
                    </list-item>
                    <list-item>
                      <p>Treating clinician initiating an order for an antipseudomonal cephalosporin or antipseudomonal penicillin.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2-3-2">
                  <title>Exclusion criteria</title>
                  <list list-type="order">
                    <list-item>
                      <p>Known receipt of &gt;1 dose of an antipseudomonal cephalosporin or antipseudomonal penicillin during the last 7 days.</p>
                    </list-item>
                    <list-item>
                      <p>Current documented allergy to cephalosporins or penicillin.</p>
                    </list-item>
                    <list-item>
                      <p>Known to be a prisoner.</p>
                    </list-item>
                    <list-item>
                      <p>Treating clinicians feel that either an antipseudomonal cephalosporin or antipseudomonal penicillin is required or contraindicated for the optimal treatment of the patient, including for more directed antibiotic therapy against known prior resistant infections or suspected sepsis with an associated central nervous system infection.</p>
                    </list-item>
                  </list>
                </sec>
              </sec>
              <sec id="s2-4">
                <title>Screening and enrolment</title>
                <p>When a treating clinician in a participating ED or ICU initiates an order for cefepime or piperacillin–tazobactam for a patient who meets all inclusion criteria, a clinical decision support (CDS) tool will (1) inform the provider of the study, (2) query the provider regarding the presence of any exclusion criteria, and if none is present, (3) enrol and randomise the patient. For patients who meet an exclusion criterion, the reason is recorded (<xref rid="F1" ref-type="fig">figure 1</xref>).</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Electronic health record-based enrolment advisor. ACORN, Antibiotic Choice On ReNal outcomes. D5W - Dextrose 5% in Water; IVPB - Intravenous Piggyback; PCN - penicillin</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2022-066995f01" position="float"/>
                </fig>
              </sec>
              <sec id="s2-5">
                <title>Analysis population</title>
                <p>The primary goal is the exploration of uncommon safety effects, therefore the population for primary analysis will include all patients who were randomised and received at least one dose of either study drug in the 168 hours (7 days) after randomisation. A sensitivity analysis will include all patients randomised, including those who never received either cefepime or piperacillin/tazobactam.</p>
              </sec>
              <sec id="s2-6">
                <title>Randomisation and treatment allocation</title>
                <p>Study group assignments are generated by computerised randomisation in a 1:1 ratio of intervention to control. Study group assignment will remain concealed until the team has confirmed the patient does not meet any exclusion criteria and the patient has been enrolled. The CDS tool will advise the clinician of group assignment following randomisation.</p>
              </sec>
              <sec id="s2-7">
                <title>Study interventions</title>
                <p>For patients assigned to cefepime, the CDS tool will guide providers to intravenous cefepime. For patients assigned to piperacillin–tazobactam, the CDS tool will guide providers to intravenous piperacillin–tazobactam. The CDS tool will display a standardised table of dose by glomerular filtration rate, but decisions regarding dose, frequency and duration will be the treating clinician’s discretion.</p>
                <p>In the 168 hours (7 days) following enrolment, any new order for cefepime or piperacillin–tazobactam will open a CDS tool, which displays group assignment and allows clinicians to (re)order the assigned antibiotic or provide a reason for ordering the non-assigned antibiotic. Similarly, if the assigned antibiotic is discontinued, the CDS tool will solicit a rationale for discontinuation, including antibiotic tailoring, newly apparent allergy to either cephalosporins or penicillins, or clinician preference.</p>
                <p>The CDS tool influences only the choice of the initial antipseudomonal antibiotic. Treating clinicians to determine concurrent administration of other antibiotics (eg, vancomycin, metronidazole), duration of therapy, escalation, de-escalation, approach to source control and use of culture and laboratory data to modify antibiotic therapy.</p>
              </sec>
              <sec id="s2-8">
                <title>Data collection</title>
                <p>Trial personnel will monitor for adverse events daily and will record the following data elements at the time of enrolment by manual review of the health record (<xref rid="SP1" ref-type="supplementary-material">online supplemental files 3 and 4</xref>):</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Presence of sepsis, defined by Sepsis-3 criteria.<xref rid="R32" ref-type="bibr">32</xref>
</p>
                  </list-item>
                  <list-item>
                    <p>Transplant recipient status.</p>
                  </list-item>
                  <list-item>
                    <p>Receipt of renal replacement therapy (RRT) prior to enrolment.</p>
                  </list-item>
                  <list-item>
                    <p>Presumed source of infection organised into groups based on previously published data.<xref rid="R33" ref-type="bibr">33</xref>
</p>
                  </list-item>
                </list>
                <p>All other data will be obtained using electronic exports from the health record. The following variables are collected:</p>
                <list list-type="order">
                  <list-item>
                    <p>Collected at baseline: age, sex, height, weight, body mass index, race, Sequential Organ Failure Assessment (SOFA) Score, active medical problems at the time of admission, active comorbidities, comorbidities and medications known to increase risk of kidney or neurologic injury at enrolment, mean arterial pressure and vasopressor use prior to antibiotic receipt, analgesia and sedation use prior to antibiotic receipt, admission to ICU versus ward.</p>
                  </list-item>
                  <list-item>
                    <p>Collected from randomisation to hospital discharge: mean arterial pressure and vasopressor use, pH, PaO<sub>2</sub>, PaCO<sub>2</sub>, respiratory rate, heart rate, oxygen saturation, temperature, lactic acid, elements of a basic metabolic panel, magnesium, elements of a complete blood count, antibiotic receipt, all microbiologic culture data, <italic toggle="yes">Clostridium difficile</italic> testing results, Confusion Assessment Method for the ICU (CAM-ICU), Richmond Agitation Sedation Score (RASS), Glasgow Coma Scale (GCS), mechanical ventilation status and variables related to ventilation, nephrology consultation, receipt of new RRT, indications for new RRT among patients who received new RRT, medications known to increase risk of kidney injury, medications known to increase risk of neurologic injury, admitting team, date of admission, days spent in the ICU, days spent in the hospital, date of intubation(s) and extubation(s), date of discharge and date of death.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-9">
                <title>Primary outcome</title>
                <p>The primary outcome will be a combination of the highest stage of AKI and death between randomisation and day 14. The stages of AKI are defined using creatinine measurements and the ‘Kidney Disease: Improving Global Outcomes (KDIGO)’<xref rid="R34" ref-type="bibr">34</xref> criteria. The score will range from 0 (best value) to 4 (worst value):</p>
                <p>0=No AKI.</p>
                <p>1=Stage 1 AKI (creatinine increased by 1.5–1.9 times baseline or increase by ≥0.3 mg/dL).</p>
                <p>2=Stage 2 AKI (creatinine increased by 2.0–2.9 times baseline).</p>
                <p>3=Stage 3 AKI (creatinine increased by ≥3.0 times baseline or increase to ≥4.0 mg/dL or new RRT).</p>
                <p>4=Death.</p>
                <p>‘Baseline’ creatinine values are defined as the lowest prior creatinine values from three different timepoints: the preillness creatinine value, the perienrolment creatinine value and the lowest prior on-study creatinine value as defined below. Death is defined as mortality from any cause occurring prior to or on the end of study day 14, censored at hospital discharge. RRT is defined as receipt of RRT at any point between randomisation and the end of study day 14, censored at hospital discharge. Patients who are receiving RRT prior to enrolment can only experience values of 0 (patient did not die) or 4 (patient died) because they are ineligible to experience changes in creatinine or new receipt of RRT that define levels 1 through 3.</p>
                <p>Patients’ preillness creatinine will be defined as the lowest serum creatinine between 12 months and 24 hours prior to enrolment. For patients for whom a value is unavailable, a preillness creatinine value will be estimated using a previously described three-variable formula (creatinine=0.74–0.2 (if female)+0.08 (if African American)+0.003×age (in years)).<xref rid="R35" ref-type="bibr">35</xref> There are no validated estimations of creatinine without race but we will evaluate the effect of social constructs by fitting models both with and without race in a sensitivity analysis.</p>
                <p>Patients’ perienrolment creatinine will be defined hierarchically using the creatinine value closest to enrolment in: (first) the 24 hours prior to enrolment, if available, and (second) the 6 hours after enrolment (if no value is available prior to enrolment). The prevalent AKI, or AKI that is present on admission and unrelated to the study intervention, will be defined by comparing the perienrolment creatinine to the preillness creatinine.</p>
                <p>On-study creatinine will be defined as any creatinine value occurring after both the time of enrolment and the time of the perienrolment creatinine value. On-study creatinine values will be used to identify incident AKI and calculate the stage of AKI for the primary outcome.</p>
                <p>The primary outcome will be calculated as follows:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Patients who survive without new RRT and do not experience an on-study creatinine value that is at least 0.3 mg/dL higher than the perienrolment value or any preceding on-study value, and whose on-study creatinine is never more than 1.5 times the perienrolment value or any preceding on-study value, will be considered not to have experienced incident AKI and will receive a value of 0 for the primary outcome.</p>
                  </list-item>
                  <list-item>
                    <p>Among patients who survive and experience AKI (have on-study creatinine value that is at 1.5 times or at least 0.3 mg/dL higher than the perienrolment value or any preceding on-study value), the score for the primary outcome will be determined by the stage of AKI and classified as follows:</p>
                    <list list-type="alpha-lower">
                      <list-item>
                        <p>A value of 1 if the highest on-study creatinine after qualifying for AKI is less than 2 times the lowest of the preillness creatinine value, the perienrolment creatinine value and the lowest prior on-study creatinine value (baseline creatinine).</p>
                      </list-item>
                      <list-item>
                        <p>A value of 2 if the highest on-study creatinine after qualifying for AKI is at least 2 times and less than 3 times the lowest of the preillness creatinine value, the perienrolment creatinine value and the lowest prior on-study creatinine value (baseline creatinine).</p>
                      </list-item>
                      <list-item>
                        <p>A value of 3 if the highest on-study creatinine after qualifying for AKI is at least 3 times the lowest of the preillness creatinine value, the perienrolment creatinine value and the lowest prior on-study creatinine value (baseline creatinine), with a maximum creatinine above 4 mg/dL, or receive new RRT.</p>
                      </list-item>
                    </list>
                  </list-item>
                  <list-item>
                    <p>Patients who die will receive a value of 4.</p>
                  </list-item>
                </list>
                <p>The mechanisms and extent of AKI with antibiotic exposure are not well understood. The primary outcome window of 14 days was chosen as it was felt to capture the period most likely to be affected by controlling antibiotics choice for 168 hours (7 days).</p>
              </sec>
              <sec id="s2-10">
                <title>Secondary outcomes</title>
                <p>We have prespecified two secondary outcomes. Major adverse kidney events within 14 days (MAKE14) is the composite outcome of death within 14 days, new RRT within 14 days or stage 2 or higher AKI at day 14, according to KDIGO creatinine criteria. The second is number of days alive and free of delirium and coma in the 14 days after enrolment (delirium and coma-free days to day 14). Delirium is defined as a positive assessment on the CAM-ICU<xref rid="R36" ref-type="bibr">36</xref> and coma is defined as an RASS of −4 or −5<xref rid="R37" ref-type="bibr">37</xref> at any point during that study day.</p>
              </sec>
              <sec id="s2-11">
                <title>Exploratory outcomes</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Exploratory renal outcomes.</p>
                    <list list-type="bullet">
                      <list-item>
                        <p>Major adverse kidney events within 28 days (MAKE28).</p>
                      </list-item>
                      <list-item>
                        <p>Highest stage of AKI or death between randomisation and day 7.</p>
                      </list-item>
                      <list-item>
                        <p>Stage 2 or higher AKI as defined in the KDIGO criteria for creatinine level within 14 days and 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>New receipt of RRT within 14 days and 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>Days alive and free of RRT during 14 days and 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>Highest creatinine level within 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>Change from preillness creatinine to the highest creatinine level within 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>Final creatinine level before hospital discharge at 28 days.</p>
                      </list-item>
                      <list-item>
                        <p>Ongoing receipt of RRT at hospital discharge or 28 days.</p>
                      </list-item>
                      <list-item>
                        <p>Nephrology consultation.</p>
                      </list-item>
                    </list>
                  </list-item>
                  <list-item>
                    <p>Exploratory neurologic outcomes.</p>
                    <list list-type="bullet">
                      <list-item>
                        <p>Worst GCS Score during the 7, 14 and 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>Delirium and coma-free days in the 28 days after enrolment.</p>
                      </list-item>
                    </list>
                  </list-item>
                  <list-item>
                    <p>Exploratory clinical outcomes.</p>
                    <list list-type="bullet">
                      <list-item>
                        <p>ICU-free, hospital-free, ventilator-free and vasopressor-free days in the 28 days after enrolment.</p>
                      </list-item>
                      <list-item>
                        <p>14-day mortality.</p>
                      </list-item>
                      <list-item>
                        <p>28-day mortality.</p>
                      </list-item>
                      <list-item>
                        <p>Disposition of patients admitted from the ED (ward vs ICU).</p>
                      </list-item>
                      <list-item>
                        <p>Escalation of antibiotics defined by subsequent receipt of meropenem, meropenem–vaborbactam, imipenem, imipenem–relebactam, cefiderocol, ceftazidime–avibactam, ceftolozane–tazobactam, tigecycline, amikacin, tobramycin, gentamicin.</p>
                      </list-item>
                    </list>
                  </list-item>
                </list>
                <p>Definition of supportive therapy-free days is available in <xref rid="SP1" ref-type="supplementary-material">online supplemental section 5</xref>.</p>
              </sec>
              <sec id="s2-12">
                <title>DSMB and interim analysis</title>
                <p>A DSMB composed of experts in critical care medicine, infectious disease and biostatistics has overseen the design of the trial and is monitoring its conduct (<xref rid="SP1" ref-type="supplementary-material">online supplemental file 6</xref>). The DSMB conducted a single interim analysis, prepared by the study biostatistician, at the anticipated halfway point of the trial after enrolment of 1025 patients. The meeting was held on 14 July 2022, and the DSMB recommended continuing the trial to completion without alteration. The stopping boundary for efficacy was prespecified as p value for the difference between groups in the primary outcome of 0.001 or less. Given current use of both interventions as a part of usual care, there was no stopping boundary for futility. The use of a conservative Haybittle-Peto boundary for efficacy will allow the final analysis to be performed using an unchanged level of significance (p=0.05). The DSMB retains the authority to recommend stopping the trial at any point, request additional data or interim analyses, or request modifications of the study protocol to protect patient safety.</p>
              </sec>
              <sec id="s2-13">
                <title>Sample size estimation</title>
                <p>As specified in the initial trial protocol, at the time of the single, planned interim analysis the DSMB oversaw a re-estimation of the planned sample size. Because (1) concurrent receipt of vancomycin has been hypothesised to be in the proposed mechanistic pathway between receipt of an antipseudomonal penicillin and AKI and (2) approximately 75% of patients in the trial concurrently receive vancomycin, the sample size was increased by 25% from 2050 to 2500 patients. The increase in sample size ensures the number of patients receiving concurrent vancomycin will be approximately 2050, consistent with the original sample size estimation. Assuming a two-sided alpha of 0.05 and a distribution of the primary outcome with approximately 70% of patients experiencing no AKI, 10% of patients experiencing stage 1 AKI, 7% of patients experiencing stage 2 AKI, 7% of patients experiencing stage 3 AKI and 6% of patients experiencing death, we calculated that enrolment of a total of 2500 patients would provide 92% statistical power to detect an OR of 0.75 in the primary analysis.</p>
              </sec>
              <sec id="s2-14">
                <title>Statistical analysis principles</title>
                <p>Analyses will be conducted following reproducible research principles using R (R Foundation for Statistical Computing, Vienna, Austria).<xref rid="R38" ref-type="bibr">38</xref> Continuous variables will be reported as mean±SD or median and IQR; categorical variables will be reported as frequencies and proportions. As a randomised controlled trial, there will be no comparison of baseline characteristics. A two-sided p value of &lt;0.05 will be used to indicate statistical significance; with just one primary outcome, no adjustment for multiplicity will be made. Two secondary outcomes are specified, one safety outcome for each treatment regimen. Since hypothesised safety concerns are independent, we will not adjust our secondary outcomes for multiplicity. For all other outcomes, emphasis will be placed on the magnitude of differences between groups rather than statistical significance.</p>
              </sec>
              <sec id="s2-15">
                <title>Main analysis of the primary outcome</title>
                <p>The main analysis will be an unadjusted, intention-to-treat comparison of the primary outcome between patients randomised to receive antipseudomonal cephalosporins versus antipseudomonal penicillins who received at least one dose of a study drug using a proportional odds regression model. The unadjusted common OR with CIs will be the primary treatment effect. If departures from the proportionality assumption are observed, then a partially proportional odds model will be constructed.</p>
              </sec>
              <sec id="s2-16">
                <title>Secondary analyses of the primary outcome</title>
                <sec id="s2-16-1">
                  <title>Multivariable modelling to account for covariates</title>
                  <p>To account for participants’ baseline status, we will include covariates in the proportional odds regression model. The following prespecified baseline covariates will be considered: age; sex; perienrolment creatinine; receipt of RRT prior to enrolment; receipt of vasopressors; receipt of mechanical ventilation; SOFA Score; presumed source of infection; enrolment location (ED vs ICU). Source of infection will be categorised as: lung, intra-abdominal (perforated viscus, ischaemic bowel, cholecystitis/cholangitis, peritonitis/abscess/small bowel obstruction, <italic toggle="yes">Clostridium difficile</italic> colitis, spontaneous bacterial peritonitis, pancreatitis, enterocolitis/diverticulitis, other intra-abdominal infections), urinary (pyelonephritis, obstructive urinary tract infection), skin and soft tissue (cellulitis/abscess/necrotizing fasciitis/decubitus ulcer, surgical site infection), other (bone/joint, primary blood stream infection, intravascular catheter, disseminated infection, central nervous system infection, endocarditis, other) and unknown.</p>
                </sec>
                <sec id="s2-16-2">
                  <title>Effect modification</title>
                  <p>We will test the interaction between the treatment effect of antipseudomonal cephalosporins versus antipseudomonal penicillins and baseline variables expected to modify the effects of treatments on the outcomes. The effect modifiers will be tested one by one by including both the main effect and the interaction term in the adjusted model. Because this study is not formally designed or powered to test for interaction, a less conservative two-sided p value for the interaction term will be used, with values less than 0.10 considered suggestive of potential interaction and values less than 0.05 considered conclusive evidence. The following variables will be considered:</p>
                  <list list-type="order">
                    <list-item>
                      <p>Location at randomisation (ED vs ICU).</p>
                    </list-item>
                    <list-item>
                      <p>Presence of sepsis (meeting Sepsis-3 criteria) at randomisation.</p>
                    </list-item>
                    <list-item>
                      <p>Receipt of vancomycin (defined as an order for vancomycin in the 12 hours before or 6 hours after randomisation).</p>
                    </list-item>
                    <list-item>
                      <p>Source of infection.</p>
                    </list-item>
                    <list-item>
                      <p>AKI at randomisation.</p>
                    </list-item>
                    <list-item>
                      <p>CKD at randomisation.</p>
                    </list-item>
                    <list-item>
                      <p>Neutropenia at randomisation.</p>
                    </list-item>
                    <list-item>
                      <p>Admitting team (medicine vs surgical).</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2-16-3">
                  <title>Sensitivity analyses of the primary outcome</title>
                  <p>To assess robustness of findings, the main analysis of the primary outcome will be repeated in several alternative populations. First, we will include all patients who were identified by the CDS tool as meeting eligibility criteria, regardless of receipt of any doses of antipseudomonal cephalosporins or antipseudomonal penicillins. Second, many patients are initiated on antibiotics in the acute setting, which are stopped as a more likely cause for their illness becomes known (eg, pulmonary embolism). We will repeat the main analysis restricted to the subset of patients that received more than 2 days (48 hours) of antipseudomonal therapy. Third, because race is a social construct, we will repeat the main analysis with those whose preillness creatinine was estimated by an equation without race as a factor. Fourth, to avoid uncertainty around the calculations of preillness creatinine, we will repeat the main analysis excluding patients with calculated preillness creatinine values. Because group assignment might influence recovery from prevalent AKI in a way that could affect calculations of the primary outcome, we will recalculate the primary outcome as a repeated measure assessed daily from randomisation to day 14 using only the preillness creatinine as the baseline creatinine.</p>
                </sec>
                <sec id="s2-16-4">
                  <title>Analysis of the secondary outcomes</title>
                  <p>Analysis of secondary outcomes will follow a similar framework to the primary analysis, with a systematic assessment of unadjusted models, adjusted models using the same set of covariates. The secondary outcome of MAKE14 will be compared between groups using a logistic regression model. Delirium and coma-free days to day 14 will be compared between groups using a proportional odds regression model, and will include the additional covariate of coma on enrolment for the adjusted model. Delirium and coma free days to day 14 will be assessed for effect modification using the same approach as the primary outcome replacing receipt of vancomycin with baseline coma.</p>
                </sec>
                <sec id="s2-16-5">
                  <title>Analyses of exploratory outcomes</title>
                  <p>Exploratory outcomes will proceed using unadjusted analyses only, with presentation of effect sizes and CIs as well as p values. Continuous outcomes will be compared with the Mann-Whitney U test and the difference in medians reported. For categorical variables, groups will be compared with the χ<sup>2</sup> test or Fischer’s exact test as appropriate and results will be expressed as a difference in proportions or ORs, each with 95% CIs.</p>
                </sec>
              </sec>
              <sec id="s2-17">
                <title>Handling of missing data</title>
                <p>In the case that a patient is enrolled, never receives RRT and is discharged alive without having a creatinine value measured following enrolment, the patient will be assumed to have no AKI. When data are missing for secondary or exploratory outcomes, complete-case analysis, excluding cases where data for the analysed outcome are missing, will be performed. There will be no imputation of missing data for these outcomes. In adjusted analyses, missing data for covariates will be imputed using multiple imputations.</p>
              </sec>
              <sec id="s2-18">
                <title>Trial status</title>
                <p>The ACORN trial is currently enrolling and started enrolment on 10 November 2021.</p>
              </sec>
              <sec id="s2-19">
                <title>Ethics and dissemination</title>
                <sec id="s2-19-1">
                  <title>Waiver of informed consent</title>
                  <p>Acutely ill patients for whom the provider is ordering broad-spectrum antibiotics in the ED or ICU are at significant risk for morbidity and mortality from their underlying illness. Most patients receiving empiric gram-negative antibiotics in routine clinical care receive either antipseudomonal cephalosporins or antipseudomonal penicillins. Any benefits or risks of these two approaches are experienced by patients receiving gram-negative antibiotics in clinical care, outside the context of research. As a requirement for enrolment in the ACORN trial, the patient’s treating clinician must have made the decision to order either antipseudomonal cephalosporins or antipseudomonal penicillins as part of routine clinical care and affirmed that either would be a safe and reasonable approach for the patient (otherwise the patient is excluded). Therefore, making the decision between the two approaches randomly through study group assignment rather than by a provider who thinks either approach is safe and reasonable for the patient was proposed to pose no more than minimal incremental risk.</p>
                  <p>Obtaining informed consent for participation in the study would be impracticable. Receipt of antibiotics in sepsis is time sensitive. Each hour delay in antibiotics in patients with sepsis is associated with an increase in mortality.<xref rid="R39" ref-type="bibr">39</xref> Attempting to obtain prospective written informed consent from patients presenting to the ED or ICU during the interval between the placement of an order for empiric antibiotics and their administration risks delaying antibiotic delivery. Moreover, acutely ill patients with sepsis are commonly delirious or unconscious, and a legally authorised representative is not consistently present at the time of initiation of antibiotics. Because the trial determines only the choice of the initial antipseudomonal antibiotic and defers decisions regarding subsequent doses of antibiotics (eg, duration of therapy, escalation, de-escalation) to treating clinicians, enrolment, trial group assignment and the primary study procedure (administration of the assigned antibiotic) commonly occurs within 1 hour of meeting eligibility criteria.</p>
                  <p>Because the study was expected to pose minimal risk and prospective informed consent was considered to be impracticable, a waiver of informed consent was requested and granted from the Vanderbilt University Medical Center IRB.</p>
                </sec>
              </sec>
              <sec id="s2-20">
                <title>Protocol changes</title>
                <p>ClinicalTrials.Gov will be updated with any amendments to the protocol as per SPIRIT guidelines (<xref rid="SP1" ref-type="supplementary-material">online supplemental file 7</xref>).</p>
              </sec>
              <sec id="s2-21">
                <title>Dissemination plan</title>
                <p>Trial results will be submitted to a peer-reviewed journal for consideration of publication and will be presented at one or more scientific conferences. Data will be made available following publication (<xref rid="SP1" ref-type="supplementary-material">online supplemental file 8</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="s3">
              <title>Conclusion</title>
              <p>To allow for a clearer and more objective interpretation of trial results, this description delineates the ACORN trial methods and analysis prior to the conclusion of enrolment.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e464">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2022-066995.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e465">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2022-066995.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Twitter:</bold> @edqain, @BradLloydVFL, @TraumaDawg</p>
              </fn>
              <fn fn-type="other">
                <p>MWS and TWR contributed equally.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Collaborators:</bold> A complete list of the members of the Vanderbilt Learning Healthcare System Platform Investigators is provided in the online supplemental file 1.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> All study authors approved the final version of this manuscript. Study concept and design: ETQ, JDC, AW, LW, JStollings, GN, PW, EDS, JW, JA, WHS, MWS and TWR. Acquisition of data: ETQ, BDL and KS. Drafting of the manuscript: ETQ, JDC, MWS and TWR. Critical revision of the manuscript for important intellectual content: ETQ, JDC, AW, LW, JSiemann, MLD, JStollings, BDL, KS, GN, PW, EDS, BD, JW, JA, WHS, MWS and TWR. Study supervision: MWS and TWR.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> The project described was supported by the VICTR Learning Healthcare System Platform under CTSA, award No. UL1 TR002243, from the National Center for Advancing Translational Sciences. It contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. ETQ was supported by the National Heart, Lung, and Blood Institute, award No. T32HL087738. JDC was supported in part by the NHLBI (K23HL153584). MWS was supported in part by the NHLBI (K23HL143053). EDS was supported by the Vanderbilt O’Brien Kidney Center P30-DK114809 for service provided through the Clinical and Translational Research Core. The funding institutions had no role in (1) conception, design, or conduct of the study, (2) collection, management, analysis, interpretation, or presentation of the data or (3) preparation, review or approval of the manuscript.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rhodes</surname><given-names>A</given-names></string-name>, <string-name><surname>Evans</surname><given-names>LE</given-names></string-name>, <string-name><surname>Alhazzani</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016</article-title>. <source>Intensive Care Med</source><year>2017</year>;<volume>43</volume>:<fpage>304</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-017-4683-6</pub-id>
<pub-id pub-id-type="pmid">28101605</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wright</surname><given-names>J</given-names></string-name>, <string-name><surname>Paauw</surname><given-names>DS</given-names></string-name></person-group>. <article-title>Complications of antibiotic therapy</article-title>. <source>Med Clin North Am</source><year>2013</year>;<volume>97</volume>:<fpage>667</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcna.2013.02.006</pub-id>
<pub-id pub-id-type="pmid">23809719</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chanderraj</surname><given-names>R</given-names></string-name>, <string-name><surname>Baker</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kay</surname><given-names>SG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes</article-title>. <source>Eur Respir J</source><year>2023</year>;<volume>61</volume>:<elocation-id>2200910</elocation-id>. <pub-id pub-id-type="doi">10.1183/13993003.00910-2022</pub-id><pub-id pub-id-type="pmid">36229047</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finfer</surname><given-names>S</given-names></string-name>, <string-name><surname>Micallef</surname><given-names>S</given-names></string-name>, <string-name><surname>Hammond</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Balanced multielectrolyte solution versus saline in critically ill adults</article-title>. <source>N Engl J Med</source><year>2022</year>;<volume>386</volume>:<fpage>815</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2114464</pub-id>
<pub-id pub-id-type="pmid">35041780</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>PW</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Meta-Analysis of a possible signal of increased mortality associated with cefepime use</article-title>. <source>Clin Infect Dis</source><year>2010</year>;<volume>51</volume>:<fpage>381</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/655131</pub-id>
<pub-id pub-id-type="pmid">20624065</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yahav</surname><given-names>D</given-names></string-name>, <string-name><surname>Paul</surname><given-names>M</given-names></string-name>, <string-name><surname>Fraser</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Efficacy and safety of cefepime: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source><year>2007</year>;<volume>7</volume>:<fpage>338</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(07)70109-3</pub-id>
<pub-id pub-id-type="pmid">17448937</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross</surname><given-names>RC</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>AN</given-names></string-name>, <string-name><surname>Tran</surname><given-names>KK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A comparison between cefepime and piperacillin-tazobactam in the management of septic shock</article-title>. <source>Cureus</source><year>2021</year>;<volume>13</volume>:<elocation-id>e18742</elocation-id>. <pub-id pub-id-type="doi">10.7759/cureus.18742</pub-id><pub-id pub-id-type="pmid">34790489</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name><surname>Heintz</surname><given-names>BH</given-names></string-name>, <string-name><surname>Mosher</surname><given-names>HJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Risk of acute kidney injury and clostridioides difficile infection with piperacillin/tazobactam, cefepime, and meropenem with or without vancomycin</article-title>. <source>Clin Infect Dis</source><year>2021</year>;<volume>73</volume>:<fpage>e1579</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1902</pub-id>
<pub-id pub-id-type="pmid">33382398</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kadomura</surname><given-names>S</given-names></string-name>, <string-name><surname>Takekuma</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study</article-title>. <source>J Pharm Health Care Sci</source><year>2019</year>;<volume>5</volume>:<fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s40780-019-0142-6</pub-id><pub-id pub-id-type="pmid">31210955</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blevins</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lashinsky</surname><given-names>JN</given-names></string-name>, <string-name><surname>McCammon</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem</article-title>. <source>Antimicrob Agents Chemother</source><year>2019</year>;<volume>63</volume>:<elocation-id>e02658-18</elocation-id>. <pub-id pub-id-type="doi">10.1128/AAC.02658-18</pub-id><pub-id pub-id-type="pmid">30782987</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Callaghan</surname><given-names>K</given-names></string-name>, <string-name><surname>Hay</surname><given-names>K</given-names></string-name>, <string-name><surname>Lavana</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: a retrospective cohort study</article-title>. <source>Int J Antimicrob Agents</source><year>2020</year>;<volume>56</volume>:<fpage>106010</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106010</pub-id><pub-id pub-id-type="pmid">32413387</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arnaud</surname><given-names>FC de S</given-names></string-name>, <string-name><surname>Libório</surname><given-names>AB</given-names></string-name></person-group>. <article-title>Attributable nephrotoxicity of vancomycin in critically ill patients: a marginal structural model study</article-title>. <source>J Antimicrob Chemother</source><year>2020</year>;<volume>75</volume>:<fpage>1031</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkz520</pub-id>
<pub-id pub-id-type="pmid">31904834</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buckley</surname><given-names>MS</given-names></string-name>, <string-name><surname>Hartsock</surname><given-names>NC</given-names></string-name>, <string-name><surname>Berry</surname><given-names>AJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit</article-title>. <source>J Crit Care</source><year>2018</year>;<volume>48</volume>:<fpage>32</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2018.08.007</pub-id>
<pub-id pub-id-type="pmid">30172962</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schreier</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Kashani</surname><given-names>KB</given-names></string-name>, <string-name><surname>Sakhuja</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin</article-title>. <source>Clin Infect Dis</source><year>2019</year>;<volume>68</volume>:<fpage>1456</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy724</pub-id>
<pub-id pub-id-type="pmid">30165426</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>HE</given-names></string-name>, <string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Chertow</surname><given-names>GM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Acute kidney injury and mortality in hospitalized patients</article-title>. <source>Am J Nephrol</source><year>2012</year>;<volume>35</volume>:<fpage>349</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1159/000337487</pub-id>
<pub-id pub-id-type="pmid">22473149</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Semler</surname><given-names>MW</given-names></string-name>, <string-name><surname>Self</surname><given-names>WH</given-names></string-name>, <string-name><surname>Wanderer</surname><given-names>JP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Balanced crystalloids versus saline in critically ill adults</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>829</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1711584</pub-id>
<pub-id pub-id-type="pmid">29485925</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Self</surname><given-names>WH</given-names></string-name>, <string-name><surname>Semler</surname><given-names>MW</given-names></string-name>, <string-name><surname>Wanderer</surname><given-names>JP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Balanced crystalloids versus saline in noncritically ill adults</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>819</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1711586</pub-id>
<pub-id pub-id-type="pmid">29485926</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gómez</surname><given-names>H</given-names></string-name>, <string-name><surname>Kellum</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Sepsis-induced acute kidney injury</article-title>. <source>Curr Opin Crit Care</source><year>2016</year>;<volume>22</volume>:<fpage>546</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0000000000000356</pub-id>
<pub-id pub-id-type="pmid">27661757</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoste</surname><given-names>EAJ</given-names></string-name>, <string-name><surname>Bagshaw</surname><given-names>SM</given-names></string-name>, <string-name><surname>Bellomo</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study</article-title>. <source>Intensive Care Med</source><year>2015</year>;<volume>41</volume>:<fpage>1411</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-015-3934-7</pub-id>
<pub-id pub-id-type="pmid">26162677</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abanades</surname><given-names>S</given-names></string-name>, <string-name><surname>Nolla</surname><given-names>J</given-names></string-name>, <string-name><surname>Rodríguez-Campello</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reversible coma secondary to cefepime neurotoxicity</article-title>. <source>Ann Pharmacother</source><year>2004</year>;<volume>38</volume>:<fpage>606</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1D322</pub-id>
<pub-id pub-id-type="pmid">14982986</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balderia</surname><given-names>PG</given-names></string-name>, <string-name><surname>Chandorkar</surname><given-names>A</given-names></string-name>, <string-name><surname>Kim</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Dosing cefepime for renal function does not completely prevent neurotoxicity in a patient with kidney transplant</article-title>. <source>J Patient Saf</source><year>2018</year>;<volume>14</volume>:<fpage>e33</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/PTS.0000000000000225</pub-id>
<pub-id pub-id-type="pmid">26102002</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Drago</surname><given-names>L</given-names></string-name>, <string-name><surname>De Vecchi</surname><given-names>E</given-names></string-name></person-group>. <article-title>The safety of cefepime in the treatment of infection</article-title>. <source>Expert Opin Drug Saf</source><year>2008</year>;<volume>7</volume>:<fpage>377</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1517/14740338.7.4.377</pub-id>
<pub-id pub-id-type="pmid">18613802</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>MB</given-names></string-name>, <string-name><surname>Bednarik</surname><given-names>J</given-names></string-name>, <string-name><surname>Lee</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Delirium monitoring in neurocritically ill patients: a systematic review</article-title>. <source>Crit Care Med</source><year>2018</year>;<volume>46</volume>:<fpage>1832</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000003349</pub-id>
<pub-id pub-id-type="pmid">30142098</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pandharipande</surname><given-names>PP</given-names></string-name>, <string-name><surname>Girard</surname><given-names>TD</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>JC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Long-Term cognitive impairment after critical illness</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>369</volume>:<fpage>1306</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1301372</pub-id>
<pub-id pub-id-type="pmid">24088092</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Girard</surname><given-names>TD</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>JC</given-names></string-name>, <string-name><surname>Pandharipande</surname><given-names>PP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Delirium as a predictor of long-term cognitive impairment in survivors of critical illness</article-title>. <source>Crit Care Med</source><year>2010</year>;<volume>38</volume>:<fpage>1513</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e3181e47be1</pub-id>
<pub-id pub-id-type="pmid">20473145</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boschung-Pasquier</surname><given-names>L</given-names></string-name>, <string-name><surname>Atkinson</surname><given-names>A</given-names></string-name>, <string-name><surname>Kastner</surname><given-names>LK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study</article-title>. <source>Clin Microbiol Infect</source><year>2020</year>;<volume>26</volume>:<fpage>333</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2019.06.028</pub-id>
<pub-id pub-id-type="pmid">31284030</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rhee</surname><given-names>C</given-names></string-name>, <string-name><surname>Dantes</surname><given-names>R</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014</article-title>. <source>JAMA</source><year>2017</year>;<volume>318</volume>:<fpage>1241</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.13836</pub-id>
<pub-id pub-id-type="pmid">28903154</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>A-W</given-names></string-name>, <string-name><surname>Tetzlaff</surname><given-names>JM</given-names></string-name>, <string-name><surname>Gøtzsche</surname><given-names>PC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials</article-title>. <source>BMJ</source><year>2013</year>;<volume>346</volume>:<elocation-id>e7586</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.e7586</pub-id><pub-id pub-id-type="pmid">23303884</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindsell</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Gatto</surname><given-names>CL</given-names></string-name>, <string-name><surname>Dear</surname><given-names>ML</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Learning from what we do, and doing what we learn: a learning health care system in action</article-title>. <source>Academic Medicine</source><year>2021</year>;<volume>96</volume>:<fpage>1291</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/ACM.0000000000004021</pub-id>
<pub-id pub-id-type="pmid">33635834</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qian</surname><given-names>ET</given-names></string-name>, <string-name><surname>Gatto</surname><given-names>CL</given-names></string-name>, <string-name><surname>Amusina</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial</article-title>. <source>JAMA Intern Med</source><year>2022</year>;<volume>182</volume>:<fpage>612</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2022.1070</pub-id>
<pub-id pub-id-type="pmid">35435937</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hasselblad</surname><given-names>M</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>J</given-names></string-name>, <string-name><surname>Kleinpell</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Promoting patient and nurse safety: testing a behavioural health intervention in a learning healthcare system: results of the DEMEANOR pragmatic, cluster, cross-over trial</article-title>. <source>BMJ Open Qual</source><year>2022</year>;<volume>11</volume>:<elocation-id>e001315</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjoq-2020-001315</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singer</surname><given-names>M</given-names></string-name>, <string-name><surname>Deutschman</surname><given-names>CS</given-names></string-name>, <string-name><surname>Seymour</surname><given-names>CW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The third International consensus definitions for sepsis and septic shock (sepsis-3)</article-title>. <source>JAMA</source><year>2016</year>;<volume>315</volume>:<fpage>801</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
<pub-id pub-id-type="pmid">26903338</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leligdowicz</surname><given-names>A</given-names></string-name>, <string-name><surname>Dodek</surname><given-names>PM</given-names></string-name>, <string-name><surname>Norena</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association between source of infection and hospital mortality in patients who have septic shock</article-title>. <source>Am J Respir Crit Care Med</source><year>2014</year>;<volume>189</volume>:<fpage>1204</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201310-1875OC</pub-id>
<pub-id pub-id-type="pmid">24635548</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><article-title>Kidney disease improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury</article-title>. <source>Kidney Int Suppl</source><year>2012</year>;<volume>2</volume>. <pub-id pub-id-type="doi">10.1038/kisup.2012.1</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Závada</surname><given-names>J</given-names></string-name>, <string-name><surname>Hoste</surname><given-names>E</given-names></string-name>, <string-name><surname>Cartin-Ceba</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A comparison of three methods to estimate baseline creatinine for rifle classification</article-title>. <source>Nephrol Dial Transplant</source><year>2010</year>;<volume>25</volume>:<fpage>3911</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfp766</pub-id>
<pub-id pub-id-type="pmid">20100732</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ely</surname><given-names>EW</given-names></string-name>, <string-name><surname>Inouye</surname><given-names>SK</given-names></string-name>, <string-name><surname>Bernard</surname><given-names>GR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU)</article-title>. <source>JAMA</source><year>2001</year>;<volume>286</volume>:<fpage>2703</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1001/jama.286.21.2703</pub-id>
<pub-id pub-id-type="pmid">11730446</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sessler</surname><given-names>CN</given-names></string-name>, <string-name><surname>Gosnell</surname><given-names>MS</given-names></string-name>, <string-name><surname>Grap</surname><given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The Richmond agitation–sedation scale</article-title>. <source>Am J Respir Crit Care Med</source><year>2002</year>;<volume>166</volume>:<fpage>1338</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.2107138</pub-id>
<pub-id pub-id-type="pmid">12421743</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Team</surname><given-names>Rs</given-names></string-name></person-group>. <article-title>RStudio: integrated development for R</article-title> [<comment>RStudio</comment>]. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Inc</publisher-name>. <comment>n.d.</comment>
<comment>Available</comment>: <uri xlink:href="http://www.rstudio.com/">www.rstudio.com/</uri>
</mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>VX</given-names></string-name>, <string-name><surname>Fielding-Singh</surname><given-names>V</given-names></string-name>, <string-name><surname>Greene</surname><given-names>JD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The timing of early antibiotics and hospital mortality in sepsis</article-title>. <source>Am J Respir Crit Care Med</source><year>2017</year>;<volume>196</volume>:<fpage>856</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201609-1848OC</pub-id>
<pub-id pub-id-type="pmid">28345952</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
